论文信息 - First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1) - 字舞流文

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)

E. Schmidt | J. Schellens | A. Hansen | D. Cho | O. Rahma | J. Weber | S. Aspeslagh | A. Hoos | S. Postel-Vinay | S. Champiat | A. Marabelle | H. Struemper | N. Somaiah | T. Bauer | A. Spreafico | M. Altan | V. Lam | Frans L Opdam | C. Ahlers | K. Autio | E. Paul | F. Opdam | N. Yanamandra | W. Ros | F. Stephen Hodi | M. Chisamore | M. McKean | J. Litton | J. Heymach | Anna Spreafico | F Stephen Hodi | Jan H M Schellens | Maura Watmuff | Sophie Postel-Vinay | Vincent K Lam | Willeke Ros | Todd M Bauer | Daniel C Cho | Jennifer K Litton | Sandrine Aspeslagh | Karen A Autio | Frans L Opdam | Meredith McKean | Neeta Somaiah | Stephane Champiat | Mehmet Altan | Osama Rahma | Elaine M Paul | Christoph M Ahlers | Helen Zhou | Herbert Struemper | Shelby A Gorman | Maura Watmuff | Kaitlin M Yablonski | Niranjan Yanamandra | Michael J Chisamore | Emmett V Schmidt | Axel Hoos | Aurelien Marabelle | Jeffrey S Weber | John V Heymach | Shelby A. Gorman | Kaitlin M. Yablonski | Kaitlin Yablonski | S. Hodi | S. P. Vinay | Twitter Osama